Edward Nash
Stock Analyst at Canaccord Genuity
(4.44)
# 330
Out of 4,963 analysts
86
Total ratings
52%
Success rate
22.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Maintains: Buy | $64 → $62 | $22.60 | +174.34% | 2 | Aug 20, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $420 → $428 | $425.06 | +0.69% | 10 | Aug 6, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $142 → $137 | $69.73 | +96.47% | 8 | Aug 1, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $28 | $7.78 | +259.90% | 1 | Jul 24, 2025 | |
| VRNA Verona Pharma | Downgrades: Hold | $107 | $105.78 | +1.15% | 10 | Jul 9, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $17.44 | +169.50% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.56 | +1,497.44% | 2 | Feb 26, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.69 | +136.69% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $48.19 | +51.48% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $37.85 | +135.14% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $14 | $2.51 | +457.77% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.12 | +614.29% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $5.23 | +282.41% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $3.25 | +146.21% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $7.20 | +136.11% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.20 | -9.09% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.39 | +12,849.64% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $30.08 | +172.61% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $3.04 | +2,531.58% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $15.78 | +204.28% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $6.90 | +9,320.29% | 1 | Nov 8, 2017 |
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $64 → $62
Current: $22.60
Upside: +174.34%
Madrigal Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $420 → $428
Current: $425.06
Upside: +0.69%
Corcept Therapeutics
Aug 1, 2025
Maintains: Buy
Price Target: $142 → $137
Current: $69.73
Upside: +96.47%
Sagimet Biosciences
Jul 24, 2025
Initiates: Buy
Price Target: $28
Current: $7.78
Upside: +259.90%
Verona Pharma
Jul 9, 2025
Downgrades: Hold
Price Target: $107
Current: $105.78
Upside: +1.15%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $17.44
Upside: +169.50%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.56
Upside: +1,497.44%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.69
Upside: +136.69%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $48.19
Upside: +51.48%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $37.85
Upside: +135.14%
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $2.51
Upside: +457.77%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.12
Upside: +614.29%
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $5.23
Upside: +282.41%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $3.25
Upside: +146.21%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $7.20
Upside: +136.11%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.20
Upside: -9.09%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.39
Upside: +12,849.64%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $30.08
Upside: +172.61%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $3.04
Upside: +2,531.58%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $15.78
Upside: +204.28%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $6.90
Upside: +9,320.29%